Abstract 261P
Background
Ovarian germ cell tumour (GCT) is a potentially curable malignancy generally occurring in young females. The impact of various social stigmas on these women is profound especially among the lower socioeconomic classes from developing countries. The data on the epidemiology and potential challenges in management will help to fine-tune our approach.
Methods
A Retrospective analysis of ovarian GCTs treated at our institute from 2011 to 2017 was carried out. Our aim was to study the epidemiology, salient features and long-term outcomes in ovarian GCTs.
Results
There were 14 benign teratomas and 35 malignant tumours. 12 were mixed GCTs ,11 were dysgerminomas, 6 were yolk sac tumours, 5 were immature teratomas and there was 1 pure Choriocarcinoma. The median age at presentation for malignant tumours was 21.14years and for benign teratomas was 40 years. Pain was the presenting complaint in 74%, mass in 20% and 5%came with ascites. Bilaterality observed in 20%dysgerminoma,14%benign teratomas and 8%mixed tumours. Those with FIGO stage1 was 58% and 38% were stage3 at presentation. Mean size of dysgerminomas was 12cm and 14cm for non-dysgerminomas. Three cases diagnosed antenatally underwent LSCS along with definitive surgery at term and another patient underwent early MTP. Fertility sparing surgery was done in 63.4% benign and 60% of malignant cases. There was no indication for chemotherapy in 6 patients. Neoadjuvant chemotherapy was given for 4 patients and adjuvant for the rest(BEP). After chemotherapy 15%developed ovarian failure. Nausea, vomiting, diarrhoea and neutropenia were the common adverse events.6 patients defaulted after surgery. All dysgerminomas and teratomas achieved complete remission and the overall rate was 93.3%. Recurrence at 45month follow-up was 18% but zero for dysgerminoma. Most recurrences were within 2years (75%). OS during the period was 88.5%.
Conclusions
Malignant ovarian GCTs occur in younger females and benign ones more in the middle age. The long-term outcomes are generally excellent. Non-dysgerminoma histology, inadequate surgery and advanced stage are poor prognostic factors. The social stigmas associated with a diagnosis of cancer seemed to adversely impact the treatment compliance and long term follow up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The presenting author.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract